Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$16.97 - $22.03 $107,471 - $139,515
6,333 Added 15.0%
48,567 $986,000
Q1 2023

May 10, 2023

BUY
$15.96 - $23.15 $674,054 - $977,717
42,234 New
42,234 $770,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $950M
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Jupiter Asset Management LTD Portfolio

Follow Jupiter Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jupiter Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Jupiter Asset Management LTD with notifications on news.